questionsmedicales.fr
Maladies du système immunitaire
Maladies auto-immunes
Maladie de Basedow
Ophtalmopathie basedowienne
Ophtalmopathie basedowienne : Questions médicales fréquentes
Termes MeSH sélectionnés :
Diagnostic
5
Ophtalmopathie
Maladie de Basedow
Thyroïdite
Imagerie par résonance magnétique
Échographie
Thyroïde
Exophtalmie
Diplopie
Paupière
Hormones thyroïdiennes
Anticorps
Thyroïde
Diagnostic différentiel
Exophtalmie
Maladies oculaires
Symptômes
5
Exophtalmie
Sécheresse oculaire
Douleur oculaire
Diplopie
Muscles oculaires
Vision
Vision
Vision floue
Troubles visuels
Paupières
Inflammation
Gonflement
Symptômes
Variabilité
Maladie
Prévention
5
Prévention
Maladie de Basedow
Thyroïde
Tabagisme
Risque
Symptômes
Stress
Gestion du stress
Santé
Examens médicaux
Détection précoce
Santé oculaire
Alimentation
Santé thyroïdienne
Santé oculaire
Traitements
5
Corticostéroïdes
Radiothérapie
Chirurgie
Corticostéroïdes
Inflammation
Symptômes
Chirurgie
Exophtalmie
Vision
Radiothérapie
Tissus orbitaires
Inflammation
Larmes artificielles
Lunettes prismatiques
Traitements non médicamenteux
Complications
5
Complications
Perte de vision
Nerfs optiques
Perte de vision
Récupération
Gravité
Esthétique
Exophtalmie
Paupières
Nerfs optiques
Inflammation
Vision
Complications
Suivi médical
Traitement
Facteurs de risque
5
Facteurs de risque
Hyperthyroïdie
Antécédents familiaux
Antécédents familiaux
Maladies thyroïdiennes
Risque
Stress
Facteurs de risque
Symptômes
Femmes
Risque
Ophtalmopathie
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Ophtalmopathie basedowienne : Questions médicales les plus fréquentes",
"headline": "Ophtalmopathie basedowienne : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Ophtalmopathie basedowienne : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-06-26",
"dateModified": "2025-03-23",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Ophtalmopathie basedowienne"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Maladie de Basedow",
"url": "https://questionsmedicales.fr/mesh/D006111",
"about": {
"@type": "MedicalCondition",
"name": "Maladie de Basedow",
"code": {
"@type": "MedicalCode",
"code": "D006111",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "C20.111.555"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Ophtalmopathie basedowienne",
"alternateName": "Graves Ophthalmopathy",
"code": {
"@type": "MedicalCode",
"code": "D049970",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Kubra Serbest Ceylanoglu",
"url": "https://questionsmedicales.fr/author/Kubra%20Serbest%20Ceylanoglu",
"affiliation": {
"@type": "Organization",
"name": "University of Health Sciences, Ulucanlar Eye Education and Research Hospital, Ankara, Turkey."
}
},
{
"@type": "Person",
"name": "Emine Malkoc Sen",
"url": "https://questionsmedicales.fr/author/Emine%20Malkoc%20Sen",
"affiliation": {
"@type": "Organization",
"name": "University of Health Sciences, Ulucanlar Eye Education and Research Hospital, Ankara, Turkey."
}
},
{
"@type": "Person",
"name": "Xin Wang",
"url": "https://questionsmedicales.fr/author/Xin%20Wang",
"affiliation": {
"@type": "Organization",
"name": "School of Basic Medical Science, Special Key Laboratory of Ocular Diseases of Guizhou Province, Zunyi Medical University, Zunyi, 563000, China."
}
},
{
"@type": "Person",
"name": "Poupak Fallahi",
"url": "https://questionsmedicales.fr/author/Poupak%20Fallahi",
"affiliation": {
"@type": "Organization",
"name": "Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy."
}
},
{
"@type": "Person",
"name": "Alessandro Antonelli",
"url": "https://questionsmedicales.fr/author/Alessandro%20Antonelli",
"affiliation": {
"@type": "Organization",
"name": "Department of Surgical, Medical and Molecular Pathology and Critical Area, University of Pisa, Pisa, Italy."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Factor VIII and Factor IX Activity Measurements for Hemophilia Diagnosis and Related Treatments.",
"datePublished": "2022-12-06",
"url": "https://questionsmedicales.fr/article/36473488",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1055/s-0042-1758870"
}
},
{
"@type": "ScholarlyArticle",
"name": "Cost-effectiveness analysis of recombinant factor IX Fc fusion protein compared with recombinant factor IX for the treatment of moderate-severe to severe hemophilia B in China.",
"datePublished": "2023-02-23",
"url": "https://questionsmedicales.fr/article/36815588",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1002/pbc.30264"
}
},
{
"@type": "ScholarlyArticle",
"name": "A factor IX variant that functions independently of factor VIII mitigates the hemophilia A phenotype in patient plasma.",
"datePublished": "2023-02-28",
"url": "https://questionsmedicales.fr/article/36863564",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.jtha.2023.02.019"
}
},
{
"@type": "ScholarlyArticle",
"name": "Current factor IX replacement options for hemophilia B and the challenges ahead.",
"datePublished": "2023-03-29",
"url": "https://questionsmedicales.fr/article/36963373",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1080/14656566.2023.2196012"
}
},
{
"@type": "ScholarlyArticle",
"name": "Factor IX inhibitors in haemophilia B: A report of National Haemophilia Registry in China.",
"datePublished": "2022-09-26",
"url": "https://questionsmedicales.fr/article/36163649",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1111/hae.14665"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Maladies du système immunitaire",
"item": "https://questionsmedicales.fr/mesh/D007154"
},
{
"@type": "ListItem",
"position": 3,
"name": "Maladies auto-immunes",
"item": "https://questionsmedicales.fr/mesh/D001327"
},
{
"@type": "ListItem",
"position": 4,
"name": "Maladie de Basedow",
"item": "https://questionsmedicales.fr/mesh/D006111"
},
{
"@type": "ListItem",
"position": 5,
"name": "Ophtalmopathie basedowienne",
"item": "https://questionsmedicales.fr/mesh/D049970"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Ophtalmopathie basedowienne - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Ophtalmopathie basedowienne",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-11",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Ophtalmopathie basedowienne",
"description": "Comment diagnostiquer l'ophtalmopathie de Basedow ?\nQuels examens sont utilisés pour le diagnostic ?\nQuels signes cliniques indiquent cette maladie ?\nLes tests sanguins sont-ils nécessaires ?\nPeut-on confondre cette maladie avec d'autres ?",
"url": "https://questionsmedicales.fr/mesh/D049970?mesh_terms=Factor+IX#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Ophtalmopathie basedowienne",
"description": "Quels sont les symptômes courants ?\nLa diplopie est-elle fréquente ?\nY a-t-il des changements dans la vision ?\nComment se manifeste l'inflammation des paupières ?\nLes symptômes peuvent-ils varier d'une personne à l'autre ?",
"url": "https://questionsmedicales.fr/mesh/D049970?mesh_terms=Factor+IX#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Ophtalmopathie basedowienne",
"description": "Peut-on prévenir l'ophtalmopathie de Basedow ?\nLe tabagisme influence-t-il la maladie ?\nComment gérer le stress pour prévenir la maladie ?\nLes examens réguliers sont-ils importants ?\nUne alimentation saine peut-elle aider ?",
"url": "https://questionsmedicales.fr/mesh/D049970?mesh_terms=Factor+IX#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Ophtalmopathie basedowienne",
"description": "Quels traitements sont disponibles ?\nLes corticostéroïdes sont-ils efficaces ?\nQuand la chirurgie est-elle nécessaire ?\nLa radiothérapie est-elle courante ?\nY a-t-il des traitements non médicamenteux ?",
"url": "https://questionsmedicales.fr/mesh/D049970?mesh_terms=Factor+IX#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Ophtalmopathie basedowienne",
"description": "Quelles sont les complications possibles ?\nLa perte de vision est-elle réversible ?\nQuels problèmes esthétiques peuvent survenir ?\nLes nerfs optiques peuvent-ils être affectés ?\nY a-t-il des risques de complications après traitement ?",
"url": "https://questionsmedicales.fr/mesh/D049970?mesh_terms=Factor+IX#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Ophtalmopathie basedowienne",
"description": "Quels sont les principaux facteurs de risque ?\nL'âge influence-t-il le risque ?\nLes antécédents familiaux jouent-ils un rôle ?\nLe stress peut-il être un facteur de risque ?\nLes femmes sont-elles plus à risque ?",
"url": "https://questionsmedicales.fr/mesh/D049970?mesh_terms=Factor+IX#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer l'ophtalmopathie de Basedow ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le diagnostic repose sur l'examen clinique, l'imagerie et des tests sanguins pour évaluer la fonction thyroïdienne."
}
},
{
"@type": "Question",
"name": "Quels examens sont utilisés pour le diagnostic ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les examens incluent l'échographie oculaire, l'IRM et les tests de la fonction thyroïdienne."
}
},
{
"@type": "Question",
"name": "Quels signes cliniques indiquent cette maladie ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les signes incluent l'exophtalmie, la diplopie, et des modifications de la paupière."
}
},
{
"@type": "Question",
"name": "Les tests sanguins sont-ils nécessaires ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, ils permettent de mesurer les niveaux d'hormones thyroïdiennes et d'anticorps."
}
},
{
"@type": "Question",
"name": "Peut-on confondre cette maladie avec d'autres ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elle peut être confondue avec d'autres causes d'exophtalmie, nécessitant un diagnostic différentiel."
}
},
{
"@type": "Question",
"name": "Quels sont les symptômes courants ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes incluent l'exophtalmie, la sécheresse oculaire, et des douleurs oculaires."
}
},
{
"@type": "Question",
"name": "La diplopie est-elle fréquente ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, la diplopie est un symptôme courant, causée par l'atteinte des muscles oculaires."
}
},
{
"@type": "Question",
"name": "Y a-t-il des changements dans la vision ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des changements visuels peuvent survenir, y compris une vision floue ou double."
}
},
{
"@type": "Question",
"name": "Comment se manifeste l'inflammation des paupières ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'inflammation peut entraîner un gonflement, une rougeur et une rétraction des paupières."
}
},
{
"@type": "Question",
"name": "Les symptômes peuvent-ils varier d'une personne à l'autre ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'intensité et la combinaison des symptômes peuvent varier considérablement."
}
},
{
"@type": "Question",
"name": "Peut-on prévenir l'ophtalmopathie de Basedow ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il n'existe pas de méthode de prévention spécifique, mais contrôler la thyroïde peut aider."
}
},
{
"@type": "Question",
"name": "Le tabagisme influence-t-il la maladie ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le tabagisme aggrave les symptômes et augmente le risque d'ophtalmopathie."
}
},
{
"@type": "Question",
"name": "Comment gérer le stress pour prévenir la maladie ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "La gestion du stress peut aider à réduire les poussées de la maladie et améliorer la santé globale."
}
},
{
"@type": "Question",
"name": "Les examens réguliers sont-ils importants ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des examens réguliers permettent de détecter précocement les signes de la maladie."
}
},
{
"@type": "Question",
"name": "Une alimentation saine peut-elle aider ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une alimentation équilibrée peut soutenir la santé thyroïdienne et oculaire."
}
},
{
"@type": "Question",
"name": "Quels traitements sont disponibles ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les traitements incluent les corticostéroïdes, la radiothérapie et la chirurgie dans les cas graves."
}
},
{
"@type": "Question",
"name": "Les corticostéroïdes sont-ils efficaces ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, ils réduisent l'inflammation et améliorent les symptômes oculaires."
}
},
{
"@type": "Question",
"name": "Quand la chirurgie est-elle nécessaire ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "La chirurgie est envisagée pour corriger l'exophtalmie sévère ou les problèmes de vision."
}
},
{
"@type": "Question",
"name": "La radiothérapie est-elle courante ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elle est utilisée pour traiter l'inflammation sévère des tissus orbitaires."
}
},
{
"@type": "Question",
"name": "Y a-t-il des traitements non médicamenteux ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des traitements non médicamenteux incluent des larmes artificielles et des lunettes prismatiques."
}
},
{
"@type": "Question",
"name": "Quelles sont les complications possibles ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications incluent la perte de vision, l'atteinte des nerfs optiques et des problèmes esthétiques."
}
},
{
"@type": "Question",
"name": "La perte de vision est-elle réversible ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Cela dépend de la gravité de l'atteinte; certaines pertes peuvent être permanentes."
}
},
{
"@type": "Question",
"name": "Quels problèmes esthétiques peuvent survenir ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des problèmes esthétiques incluent l'exophtalmie et des modifications des paupières."
}
},
{
"@type": "Question",
"name": "Les nerfs optiques peuvent-ils être affectés ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'inflammation peut entraîner une compression des nerfs optiques, affectant la vision."
}
},
{
"@type": "Question",
"name": "Y a-t-il des risques de complications après traitement ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des complications peuvent survenir même après un traitement, nécessitant un suivi."
}
},
{
"@type": "Question",
"name": "Quels sont les principaux facteurs de risque ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les facteurs incluent l'hyperthyroïdie, le tabagisme et des antécédents familiaux."
}
},
{
"@type": "Question",
"name": "L'âge influence-t-il le risque ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le risque augmente généralement avec l'âge, surtout chez les femmes de 30 à 50 ans."
}
},
{
"@type": "Question",
"name": "Les antécédents familiaux jouent-ils un rôle ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, un historique familial de maladies thyroïdiennes augmente le risque d'ophtalmopathie."
}
},
{
"@type": "Question",
"name": "Le stress peut-il être un facteur de risque ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le stress peut déclencher ou aggraver les symptômes de l'ophtalmopathie."
}
},
{
"@type": "Question",
"name": "Les femmes sont-elles plus à risque ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les femmes sont plus souvent touchées par l'ophtalmopathie de Basedow que les hommes."
}
}
]
}
]
}
Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale
Validation scientifique effectuée le 23/03/2025
Contenu vérifié selon les dernières recommandations médicales
4 publications dans cette catégorie
Affiliations :
University of Health Sciences, Ulucanlar Eye Education and Research Hospital, Ankara, Turkey.
Publications dans "Ophtalmopathie basedowienne" :
4 publications dans cette catégorie
Affiliations :
University of Health Sciences, Ulucanlar Eye Education and Research Hospital, Ankara, Turkey.
Publications dans "Ophtalmopathie basedowienne" :
3 publications dans cette catégorie
Affiliations :
School of Basic Medical Science, Special Key Laboratory of Ocular Diseases of Guizhou Province, Zunyi Medical University, Zunyi, 563000, China.
Publications dans "Ophtalmopathie basedowienne" :
3 publications dans cette catégorie
Affiliations :
Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy.
Publications dans "Ophtalmopathie basedowienne" :
3 publications dans cette catégorie
Affiliations :
Department of Surgical, Medical and Molecular Pathology and Critical Area, University of Pisa, Pisa, Italy.
Publications dans "Ophtalmopathie basedowienne" :
3 publications dans cette catégorie
Affiliations :
Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.
Publications dans "Ophtalmopathie basedowienne" :
3 publications dans cette catégorie
Affiliations :
Department of Endocrinology and Metabolism, Shunde Hospital of Southern Medical University (The First People's Hospital of Shunde), Foshan, China.
The Second School of Clinical Medicine, Southern Medical University, Guangzhou, China.
Publications dans "Ophtalmopathie basedowienne" :
3 publications dans cette catégorie
Affiliations :
Biomedical Commercialization Center, Taipei Medical University, Taipei 11031, Taiwan.
Publications dans "Ophtalmopathie basedowienne" :
3 publications dans cette catégorie
Affiliations :
Department of Ophthalmology, Taipei Veterans General Hospital, Taipei 11217, Taiwan.
School of Medicine, National Yang Ming University, Taipei 11221, Taiwan.
School of Medicine, National Yang Ming Chiao Tung University, Hsinchu 30010, Taiwan.
Publications dans "Ophtalmopathie basedowienne" :
3 publications dans cette catégorie
Affiliations :
Department of Ophthalmology, National Taiwan University Hospital, Taipei 100225, Taiwan.
Publications dans "Ophtalmopathie basedowienne" :
3 publications dans cette catégorie
Affiliations :
Department of Ophthalmology, National Taiwan University Hospital, Taipei 100225, Taiwan.
Publications dans "Ophtalmopathie basedowienne" :
2 publications dans cette catégorie
Affiliations :
Department of Ophthalmology, Changzheng Hospital of Naval Medicine University, Shanghai, China.
Publications dans "Ophtalmopathie basedowienne" :
2 publications dans cette catégorie
Affiliations :
Department of Biochemistry and Pharmacogenomics, Faculty of Pharmacy, Medical University of Warsaw, Warsaw, Poland.
Laboratory of Biochemistry and Clinical Chemistry at the Centre for Preclinical Research, Medical University of Warsaw, Warsaw, Poland.
Publications dans "Ophtalmopathie basedowienne" :
2 publications dans cette catégorie
Affiliations :
Department of Internal Medicine and Endocrinology, Medical University of Warsaw, Warsaw, Poland.
Publications dans "Ophtalmopathie basedowienne" :
2 publications dans cette catégorie
Affiliations :
Chair and Department of Biochemistry, First Faculty of Medicine, Medical University of Warsaw, Warsaw, Poland.
Publications dans "Ophtalmopathie basedowienne" :
2 publications dans cette catégorie
Affiliations :
Department of Otolaryngology, Medical Center for Postgraduate Education, Warsaw, Poland.
Publications dans "Ophtalmopathie basedowienne" :
2 publications dans cette catégorie
Affiliations :
Department of Otolaryngology, Medical Center for Postgraduate Education, Warsaw, Poland.
Publications dans "Ophtalmopathie basedowienne" :
2 publications dans cette catégorie
Affiliations :
Chair and Department of Biochemistry, First Faculty of Medicine, Medical University of Warsaw, Warsaw, Poland.
Department of Otolaryngology, Medical Center for Postgraduate Education, Warsaw, Poland.
Publications dans "Ophtalmopathie basedowienne" :
2 publications dans cette catégorie
Affiliations :
Department of Ophthalmology, Third Xiangya Hospital, Central South University, Yuelu District, 138 Tongzipo Road, Changsha, 410013, Hunan, People's Republic of China.
Publications dans "Ophtalmopathie basedowienne" :
2 publications dans cette catégorie
Affiliations :
Department of Ophthalmology, Third Xiangya Hospital, Central South University, Yuelu District, 138 Tongzipo Road, Changsha, 410013, Hunan, People's Republic of China. weixiong420@csu.edu.cn.
Publications dans "Ophtalmopathie basedowienne" :
Accurate measurement of clotting factors VIII (FVIII) or IX (FIX) is vital for comprehensive diagnosis and management of patients with hemophilia A or B. The one-stage activated partial thromboplastin...
To evaluate the lifetime cost-effectiveness of recombinant factor IX Fc fusion protein (rFIXFc) and recombinant factor IX (rFIX) for the treatment of hemophilia B (HB) in China....
We developed a decision-analytic Markov model including three health states: alive, requiring surgery, and dead. This model estimated the lifetime cost and quality-adjusted life-years (QALYs) of proph...
Lifetime cost, QALYs, and the incremental cost-effectiveness ratio were calculated, and the results were compared with willingness-to-pay (WTP) thresholds of one to three times the gross domestic prod...
RFIXFc was associated with lower cost and more QALYs than rFIX in both scenarios, which suggested that it is a dominant strategy (more effective and cheaper) for moderate-severe to severe HB in China....
Compared with rFIX, rFIXFc appears to be a cost-effective option for the lifetime management of moderate-severe to severe HB patients in China....
Recombinant factor (F)IX-FIAV has previously been shown to function independently of activated FVIII (FVIIIa) and ameliorate the hemophilia A (HA) phenotype in vitro and in vivo....
The aim of this study was to assess the efficacy of FIX-FIAV in plasma from HA patients using thrombin generation (TG) and intrinsic clotting activity (activated partial thromboplastin time [APTT]) an...
Plasma obtained from 21 patients with HA (>18 years; 7 mild, 7 moderate, and 7 severe patients) was spiked with FIX-FIAV. The FXIa-triggered TG lag time and APTT were quantified in terms of FVIII-equi...
The linear, dose-dependent improvement in the TG lag time and APTT reached its maximum with approximately 400% to 600% FIX-FIAV in severe HA plasma and with approximately 200% to 250% FIX-FIAV in nons...
FIX-FIAV is capable of increasing the FVIII-equivalent activity and coagulation activity in plasma from HA patients, thereby mitigating the HA phenotype. Hence, FIX-FIAV could serve as a potential tre...
Therapy for hemophilia B is aimed at replacing the congenital deficiency of coagulation factor IX (FIX). For replacement therapy, several FIX concentrates derived from donated human plasma or engineer...
In this review, we explore the current FIX replacement options for hemophilia B patients by analyzing the outcomes of their main clinical trials. We cover advances in the FIX molecules with extended h...
The recent introduction of recombinant EHL FIX products has represented a major advance in the therapeutic management of hemophilia B patients, permitting both a reduction of treatment burden and impr...
The development of inhibitors against factor FIX (FIX) is the most serious complication of FIX replacement therapy in haemophilia B (HB) patients. Currently, only few cohorts of HB inhibitor patients ...
This Chinese nationwide study of HB inhibitor patients explored their risk factors for FIX inhibitor development and experience on their management....
We retrospectively analysed patient characteristics, F9 genotypes, treatment strategies and outcomes of HB inhibitor patients registered to the Chinese National Registry and Patient Organization Regis...
Forty-four unique HB inhibitor patients were identified in 4485 unique HB patients registered by year 2021 to the two Registries. Inhibitor diagnosis were usually delayed and the low prevalence (.98%)...
This study reports the largest Chinese cohort of HB inhibitor patients. Large deletions were most significantly associated with inhibitor development. Low-dose ITI might be feasible for FIX inhibitor ...
Based on observations indicating that the γ-carboxylase enzyme has a lower affinity for the protein C (PC) propeptide and that the γ-carboxylase region in the PC propeptide has a higher net charge, ex...
Continuous factor VIII (FVIII) or factor IX (FIX) infusions are commonly used for patients with hemophilia A (HA) or B (HB) undergoing surgery to secure perioperative hemostasis. To describe differenc...
The development of inhibitory antibodies (inhibitors) in persons with hemophilia B (PwHB) causes significant morbidity. Data on the impact of the F9 variant and immune tolerance induction (ITI) outcom...
Persons with severe HB in the Nordic countries were enrolled and information on F9 variants, inhibitors, ITI and complications were collected. Analyses of anti-FIX antibodies with a fluorescence-immun...
Seventy-nine PwHB were enrolled. Null variants were seen in 33 (42 %) PwHB and 12 (15 %) had a current or former inhibitor. Eleven (92 %) of the inhibitor patients had experienced allergic manifestati...
A high proportion of severe F9 gene defects among persons with severe HB in the Nordic countries may explain the observed relatively high prevalence of inhibitors. ITI success was independent of the F...
An important aspect of improving care for people with hemophilia B (HB) is developing optimal treatment strategies. Here we aimed to provide in-silico evidence, comparing the estimated optimal posolog...
The associations of plasma factor VIII (FVIII) and factor IX (FIX) levels with risk of venous thromboembolism (VTE) are not well defined. We performed a systematic review and meta-analysis of these as...
Random effects inverse-variance weighted meta-analysis was used to estimate pooled odds ratios for comparisons across equal quartiles of the distributions and 90 % thresholds (higher versus lower), an...
Among 15 studies (5327 cases) the pooled odds ratio of VTE for the fourth versus first quarter was 3.92 (95 % confidence interval 1.61, 5.29) for FVIII level; and among 7 studies (3498 cases) 1.57 (1....
We confirm increases in risk of VTE across population distributions of FVIII and FIX levels. Levels above the 90th percentile have almost twice the risk for FIX level compared to levels below; three-f...